Literature DB >> 29674422

A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies.

Denise S O'Keefe1, Dean J Bacich1, Steve S Huang2, Warren D W Heston3.   

Abstract

In this review, we cover the evolution of knowledge on the biology of prostate-specific membrane antigen (PSMA) and its translation to therapy. The usual key to discovery is a realistic model for experimentation and for testing a hypothesis. A realistic model is especially needed in the case of the human prostate, which differs significantly from the prostate of species often used as research models. We will emphasize the genetic characterization of PSMA, the nature of the PSMA protein, and its role as a carboxypeptidase, with differing important substrates and products in different tissues. We give special prominence to the importance of PSMA as a target for imaging and therapy in prostate cancer and its underdeveloped role for imaging and targeting the neovasculature of tumors other than prostate cancer. Lastly, we bring attention to its importance in other nonprostatic tissues.
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  angiogenesis; endoradiotherapy; folate; inflammatory bowel disease; prostate cancer; tumor neovasculature

Mesh:

Substances:

Year:  2018        PMID: 29674422      PMCID: PMC6910646          DOI: 10.2967/jnumed.117.203877

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  59 in total

Review 1.  Opposing roles of folate in prostate cancer.

Authors:  Kevin J Rycyna; Dean J Bacich; Denise S O'Keefe
Journal:  Urology       Date:  2013-08-28       Impact factor: 2.649

2.  A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.

Authors:  R L Sokoloff; K C Norton; C L Gasior; K M Marker; L S Grauer
Journal:  Prostate       Date:  2000-05-01       Impact factor: 4.104

3.  Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.

Authors:  J K Troyer; M L Beckett; G L Wright
Journal:  Prostate       Date:  1997-03-01       Impact factor: 4.104

Review 4.  Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.

Authors:  Klaus Kopka; Martina Benešová; Cyril Bařinka; Uwe Haberkorn; John Babich
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

5.  Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid.

Authors:  Veronica Yao; Clifford E Berkman; Joseph K Choi; Denise S O'Keefe; Dean J Bacich
Journal:  Prostate       Date:  2010-02-15       Impact factor: 4.104

6.  Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene.

Authors:  D S O'Keefe; S L Su; D J Bacich; Y Horiguchi; Y Luo; C T Powell; D Zandvliet; P J Russell; P L Molloy; N J Nowak; T B Shows; C Mullins; R A Vonder Haar; W R Fair; W D Heston
Journal:  Biochim Biophys Acta       Date:  1998-11-26

7.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.

Authors:  Bernard F Cole; John A Baron; Robert S Sandler; Robert W Haile; Dennis J Ahnen; Robert S Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard I Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Douglas J Robertson; Gerald J Beck; John H Bond; Tim Byers; Jack S Mandel; Leila A Mott; Loretta H Pearson; Elizabeth L Barry; Judy R Rees; Norman Marcon; Fred Saibil; Per Magne Ueland; E Robert Greenberg
Journal:  JAMA       Date:  2007-06-06       Impact factor: 56.272

8.  Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis.

Authors:  Veronica Yao; Anil Parwani; Christoph Maier; Warren DeWayne Heston; Dean John Bacich
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 9.  Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.

Authors:  J J Vornov; K R Hollinger; P F Jackson; K M Wozniak; M H Farah; P Majer; R Rais; B S Slusher
Journal:  Adv Pharmacol       Date:  2016-03-18

10.  Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.

Authors:  Charalambos Kaittanis; Chrysafis Andreou; Haley Hieronymus; Ninghui Mao; Catherine A Foss; Matthias Eiber; Gregor Weirich; Palak Panchal; Anuradha Gopalan; Juan Zurita; Samuel Achilefu; Gabriela Chiosis; Vladimir Ponomarev; Markus Schwaiger; Brett S Carver; Martin G Pomper; Jan Grimm
Journal:  J Exp Med       Date:  2017-11-15       Impact factor: 14.307

View more
  34 in total

Review 1.  Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells.

Authors:  Candice Ashmore-Harris; Madeleine Iafrate; Adeel Saleem; Gilbert O Fruhwirth
Journal:  Mol Ther       Date:  2020-03-20       Impact factor: 11.454

Review 2.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

Review 3.  Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Authors:  Chiara Pozzessere; Maria Bassanelli; Anna Ceribelli; Sazan Rasul; Shuren Li; John O Prior; Francesco Cicone
Journal:  Curr Urol Rep       Date:  2019-10-11       Impact factor: 3.092

4.  Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.

Authors:  Kyle Current; Catherine Meyer; Clara E Magyar; Christine E Mona; Joel Almajano; Roger Slavik; Andreea D Stuparu; Chloe Cheng; David W Dawson; Caius G Radu; Johannes Czernin; Katharina Lueckerath
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

Review 5.  Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer.

Authors:  Michael Sun; Muhammad Junaid Niaz; Muhammad Obaid Niaz; Scott T Tagawa
Journal:  Curr Oncol Rep       Date:  2021-03-29       Impact factor: 5.075

6.  E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Authors:  Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-19       Impact factor: 9.236

7.  PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?

Authors:  Winfried Brenner; Joachim Strobel; Vikas Prasad
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057

Review 8.  [Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].

Authors:  Ergela Hasa; Thomas Langbein; Matthias Eiber; Karina Knorr
Journal:  Radiologe       Date:  2021-08-05       Impact factor: 0.635

9.  Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera.

Authors:  Philipp E Hartrampf; Bernhard Petritsch; Andreas K Buck; Sebastian E Serfling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-28       Impact factor: 9.236

Review 10.  More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond.

Authors:  Anniina Hyväkkä; Verneri Virtanen; Jukka Kemppainen; Tove J Grönroos; Heikki Minn; Maria Sundvall
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.